Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

While immune checkpoint inhibitors (ICIs) have ushered in major changes in standards of
care for many solid tumor malignancies, primary and acquired resistance is common …

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …

For many cancer types, the immune system plays an essential role in their development and
growth. Based on these rather novel insights, immunotherapeutic strategies have been …

Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been
approved for the treatment of hormone receptor-positive breast cancer. In this study, we use …

Following infection, T cells differentiate into a heterogeneous population of effector T cells
that can mediate pathogen clearance. A subset of these effector T cells possesses the ability …

Simple Summary Over the past decade, cell-based immunotherapy has become a powerful
strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of …

Treatment with monoclonal antibody specific for cytotoxic T lymphocyte–associated antigen
4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective …

Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) has been
tested in advanced melanoma patients at various centers. We conducted a systematic …